The vaccine administered this time is manufactured by Pfizer. It helps prevent the onset of COVID-19.
| Product Name | COMIRNATY RTU Intramuscular Injection (Single-dose vial) |
|---|---|
| Efficacy and Indications | Prevention of infections caused by SARS-CoV-2 |
| Eligible Recipients | [Pediatric Use] Ages 5–11 |
| Dosage | 0.3 mL per dose |
| Price | ¥17,500 (¥19,250 tax included) ※This service is available by phone reservation only. |
※Even after vaccination, it is necessary to continue taking appropriate infection prevention measures.
People who fall under the following categories cannot receive this vaccine.
If you think any of these apply to you, please be sure to inform your doctor during the pre-vaccination consultation.
(※1) A clear fever is generally defined as a body temperature of 37.5°C or higher. However, even if the temperature is below 37.5°C, it may still be considered a fever depending on the person’s usual baseline temperature.
(※2) Symptoms suggestive of anaphylaxis include anaphylactic reactions or multiple systemic symptoms such as widespread skin and mucosal manifestations, wheezing, difficulty breathing, rapid heartbeat, and low blood pressure.
People Who Should Take Precautions Before Receiving This Vaccine
If any of the following apply to you, please be aware that special caution may be needed when receiving this vaccine. If you think any of these conditions may apply, be sure to inform your doctor during the pre-vaccination consultation.
If you are pregnant, may be pregnant, or are breastfeeding, please be sure to inform your doctor during the pre-vaccination consultation.
This vaccine contains adjuvants that have not been used in previous vaccines.
If you have ever experienced hypersensitivity or allergic reactions to medications in the past, you must inform your doctor during the consultation before vaccination.
The main side effects include pain at the injection site, headache, joint and muscle pain, fatigue, chills, and fever. In rare cases, serious side effects such as shock or anaphylaxis may occur. Since this is a new type of vaccine, there may be symptoms that have not yet been identified. If you experience any concerning symptoms after vaccination, please consult the administering doctor or your primary care physician.
Although extremely rare, mild cases of myocarditis or pericarditis have been reported after vaccination (*). If you experience symptoms such as chest pain, palpitations, shortness of breath, or swelling within a few days after vaccination, seek medical attention immediately.
(*) These cases are more common after the second dose than the first, and tend to occur more frequently in young people, especially males.
In rare cases, vaccination may cause health problems such as illness or lasting disabilities. Although such cases are extremely uncommon, they cannot be entirely eliminated, which is why a relief system has been established.
This vaccine is a messenger RNA (mRNA) vaccine that contains mRNA encoding the spike protein of SARS-CoV-2 (a protein necessary for the virus to enter human cells), encapsulated in a lipid nanoparticle. Once administered, the mRNA is taken up into human cells, where it directs the production of the viral spike protein. This, in turn, induces the production of neutralizing antibodies and a cellular immune response against the spike protein, thereby helping to prevent infection caused by SARS-CoV-2.
This product contains the following ingredients.
| Active Ingredient | BNT162b2 (also known as Tozinameran or Comirnaty) |
|---|---|
| Additives |
|
| Active Ingredient | BNT162b2 (also known as Tozinameran or Comirnaty) |
|---|---|
| Additives |
|
